Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case

ANTONIO ROSSI, GIUSEPPE COLANTUONI, NICOLA CANTORE, LUIGI PANICO, GIOVANNI DE CHIARA, UMBERTO FERBO and CESARE GRIDELLI
Anticancer Research January 2004, 24 (1) 317-320;
ANTONIO ROSSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPE COLANTUONI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLA CANTORE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUIGI PANICO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIOVANNI DE CHIARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
UMBERTO FERBO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CESARE GRIDELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Overexpression of HER-2/neu in breast cancer has been associated with more aggressive disease and poor overall survival. Trastuzumab, a recombinant humanized monoclonal antibody with high affinity for the HER-2 protein, inhibits the growth of breast cancer cells overexpressing HER-2. Trastuzumab showed, as second-line treatment, 15% of objective response in metastatic breast cancer. Bone marrow metastases are detectable in 23% of the patients with advanced breast cancer at first relapse and this rate increases in patients with metastatic disease. We report a case of a complete response of bone marrow metastases from breast cancer using a 3-weekly trastuzumab schedule, in a heavily pretreated patient with severe symptomatic pancitopenia.

  • Received September 1, 2003.
  • Accepted October 14, 2003.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (1)
Anticancer Research
Vol. 24, Issue 1
January-February 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case
ANTONIO ROSSI, GIUSEPPE COLANTUONI, NICOLA CANTORE, LUIGI PANICO, GIOVANNI DE CHIARA, UMBERTO FERBO, CESARE GRIDELLI
Anticancer Research Jan 2004, 24 (1) 317-320;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case
ANTONIO ROSSI, GIUSEPPE COLANTUONI, NICOLA CANTORE, LUIGI PANICO, GIOVANNI DE CHIARA, UMBERTO FERBO, CESARE GRIDELLI
Anticancer Research Jan 2004, 24 (1) 317-320;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey
  • Google Scholar

More in this TOC Section

  • Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI
  • Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
  • Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire